Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
Jefferies, the world’s only independent full-service global investment banking firm, has served companies and investors for over 55 years. Headquartered in New York, with offices in over 30 cities around the world, the firm provides clients with capital markets and financial advisory services, institutional brokerage and securities research, as well as wealth management. The firm provides research and execution services in equity, fixed income, and foreign exchange markets, as well as a full range of investment banking services including underwriting, mergers and acquisitions, restructuring and recapitalization, and other advisory services, with all businesses operating in the Americas, Europe and Asia. With over 100 healthcare investment bankers covering more than 780 companies, Jefferies healthcare is one of the most sizable healthcare investment bank teams. It has strong track record in executing Chinese healthcare transactions and demonstrates solid cross border capabilities that connect Chinese buyers with global opportunities. The investment banking team deeply covers across various sectors including biotech, medtech, pharma, diagnosis and healthcare services
Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO have been located in BioBAY. More than 10000 scientists and professionals have come to join this dynamic innovative community.
BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:
- Cold Spring Harbor Asia Conference Centre — cutting-edge academic resources and global technical communication
- BioTOP — one-stop professional solutions for biomedical companies, including analysis & test, GMP verification, biomaterials trading, training, etc.
- BioBAY Sangtian Island — commercialization base for high-tech drug, medical device and IVD companies
- BioBAY Changshu — top class industrial base for biomedical industry with international advanced standards
6 Dimensions Capital is a leading healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States. The firm currently has US$1.6 billion assets under management through 4 US dollar-denominated and 3 RMB-denominated funds with offices in Shanghai, Boston, Hong Kong and San Francisco.
6 Dimensions Capital was formed in May 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures, two prominent and complementary China-U.S. healthcare investment firms. The merger has created a powerhouse that aims to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.
Eight Roads Ventures is a global venture capital firm that backs entrepreneurs with aspirations for greatness.It has over 20 years of venture capital experience in China and has supported over 80 companies in the country’s healthcare, enterprise technology, Fintech and consumer technology sectors. As the proprietary investment arm of Fidelity International Limited, Eight Roads is committed to building bold and meaningful businesses. Including its associated funds, it has offices in China, Japan, UK, India and the US.
Eight Roads Ventures led successful investments in China, including Alibaba, China PnR, Wuxi PharmaTech, Hile, Innovent, Adagene and Hua Medicine. It launched its first USD 250 m China Healthcare Fund in 2017.
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of eight clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.
For more information, please visit www.ascentagepharma.com.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,200 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.
CD Capital is a venture capital founded in 2013, specialized in investment in the medical and healthcare industry. It is currently managing a number of USD funds, RMB funds and special purpose funds with a total size over RMB 4 Billion. CD Capital is operated by a professional team with diversified and profound industry background. Under the management of this experienced team, CD Capital has made investment in more than 30 high-potential companies and has earned a sound return from investments that have exited. CD Capital continuously observes the global trend of medical science and technology, dig deep into the development opportunity in Chinese market, and make their overall investment strategy based on their unique insight into the medical and healthcare industry. In this way, CD Capital commits to bringing explicit benefits to its LPs and investees.
Learn more at www.cd-pe.com.
GenScript Biotech Corporation (01548.HK) is a world-leading provider of reagent services and catalog products for researchers in basic life sciences, translational and biomedical fields as well as biomedical enterprises involved in pre-clinical bio-pharmaceutical development. Through its global operating centers located in the United States, Hong Kong, Ireland, the Netherlands, Japan and China, GenScript maintains strong collaboration with more than 300,000 customers from more than 100 countries to fulfill its mission in making people and nature healthier through biotechnology.
Founded in 2015, Nanjing Legend Biotechnology Co., Ltd. is a wholly-owned subsidiary of GenScript Biotech Corporation. Legend Biotech specializes in developing cell therapy products. LCAR-B38M, first product candidate of Legend Biotech, is a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy. The novel dual-epitope design of the BCMA targeting domain facilitates tight binding to BCMA, which is highly expressed on primary myeloma cells and plasma cells. In the future, Legend Biotech will building a robust pipeline in solid and liquid tumors, and looking to expand research into infectious disease areas.
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$14 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 400 private companies across a wide range of therapeutic categories and stages of development. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 40 companies.
For More information, please vist www.orbimed.com.
In 1982, Sanofi opened its first office in China. Sanofi China has a diversified business that ranges from pharmaceuticals and human vaccines to consumer healthcare. Sanofi’s China headquarters in Shanghai are supported by 11 offices in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi. Sanofi has around 9,600 employees in China. Sanofi has three manufacturing facilities in China to meet the increasing demand of the domestic market. These plants are located in Beijing, Hangzhou and Shenzhen. Sanofi operates the China R&D Center and Asia Pacific R&D Hub in Shanghai, Global R&D Operations in Chengdu, and Global Research Institute in Suzhou. Sanofi’s R&D focuses on unmet medical needs, such as oncology, immunology, and metabolic diseases in China and the rest of the world.
SS&C Intralinks, recently acquired by SS&C Technologies, is a pioneer of the virtual data room, enabling and securing the flow of information by facilitating M&A, capital raising and investor reporting. SS&C Intralinks has earned the trust and business of more than 99 percent of the Fortune 1000 and has executed over US$34.7 trillion worth of financial transactions on its platform.
Intralinks has become the preferred platform among life sciences professionals. We work closely with the pharmaceutical companies and healthcare companies to help them facilitating licensing, clinical trial, safety document distribution process. Our solution can help our clients to improve drug development success rates, enhance compliance, build better partnerships and commercialize faster.
Zai Lab (NASDAQ: ZLAB) is a China and US-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and addressing unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 400 licensing and acquisition opportunities and raise over USD 500 million in funding in China.
Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 5,000 attendees.
Consulting: ChinaBio helps global life science companies to define and execute a successful strategy in China.
Capital: ChinaBio launched its first VC fund in 2014 focused on bringing Western companies and technologies to China.
Publishing: ChinaBio® Today is the most widely read online and email newsletter on China's life science industry, with over 18,000 readers.
Our mission is simple: create the best, most innovative events to provide you with the latest business information and the greatest opportunity to network with your peers and new potential business partners.
Since 2008, Lychee Group has helped launch some of the longest running and most reputable life sciences conferences in China including: ChinaTrials: Clinical Development Leaders' Summit, China Healthcare Investment Conference (CHIC), China Medical Affairs Summit, DeviceChina, BioCentury's China Healthcare Summit and Healthcare Capital & Connections Summit (HCCS).
Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.
BioCentury and BayHelix Present: The 6th China Healthcare Summit
China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry.
Six years ago, the first China Healthcare Summit asked how the nation would build the “Bridge to Innovation.” In 2019, we examine how China is now actually building the Bridge to Global Healthcare. A full two-day program highlighted by dialog among China-facing biotech innovators and their globally-facing Chinese counterparts.
The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting.
BioCentury is the essential source of intelligence for a global audience of biotech and pharmaceutical company professionals, investors, researchers, service providers and industry stakeholders who demand deep industry knowledge, data-driven analysis, independent perspective and a commitment to accuracy. Our insight, trusted reporting and in-depth analysis are built on independent, objective surveillance of the biotechnology sector, producing the industry's most respected journals and data solution resources, since 1993.
Founded in 2002, GBI (www.gbihealth.com) is an information, applications and services company focused on the healthcare industry. It boasts a diverse portfolio of marketing intelligence solutions that enable organizations and individuals to make data-driven decisions and communicate more effectively. Over 15 years of development, GBI has built a global presence with around 200 staff across four locations in Shanghai, Beijing, São Paolo, and Washington, DC. Our first database product was launched in 2009, and we have now built a portfolio based around the flagship brands of SOURCE, DEVINT, METRIX and NAVIS, covering the markets of China, Latin America, and the United States. GBI is now a trusted provider for the pharmaceutical and medtech industries, with established long-term partnerships with multinational industry players.
Global Bio & Investment Monthly based in Taiwan, is the professional media platform focus on biotechnology, biopharmaceutical and healthcare industry. We are committed to providing in-depth first-hand information covered the trend of technology, market and investment of biotech industry. We are served as the medium to connect within the industrial value chain. Our vision is to promote the promising health and wealth for global biotech industry.
GlobalData is a leading data analytics, market research and consulting service company listed on the London Stock Exchange with over 3000 staff and 23 offices around the globe. We serve over 4,000 world's largest companies with over 600 healthcare analysts by gaining insights into competitors, evaluating market opportunities, and provide strategic opinions in pharmaceutical, biotechnological and medical devices industries. From research and development, clinical trials, business developments to investment due diligence, our clients can make better business decisions on our fully integrated one-stop intelligence center platform.
Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions. In addition, we together with our partners in Europe provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports.
The New Drug Founders Club was founded in April, 2015, to form a network for founders of companies focusing on innovative new drug R&D and of companies providing relevant services. The club is highly prestigious in that only founders of such companies and people well-recognized for having special and major contributions to new drug R&D in China (including China R&D heads of multinational companies, R&D heads of major domestic companies, partners of VC, and other nationally recognized leaders in new drug R&D) can be admitted to the club. This feature distinguish this club from any other professional organizations in China or the world. Currently there are about 268 members in the club, with several new applications reviewed for approval every month.
China’s biotech scene has been exploding over the past 2 years. Chinese investors are not just pouring billions into new Asian startups, they’re also jumping into global syndicates backing a new generation of startups in the US and Europe as well.
This October, we’ll be bringing top industry players in China and the US to Shanghai for the inaugural run of the US-China Biopharma Innovation and Investment Summit. For US companies, this is a chance to explore the most important emerging healthcare market in the world, with a forecast on drug innovation and a chance to meet potential partners. And you’ll hear directly from a group of headliners on both sides of the Pacific on the most important developments you need to be aware of, with a special focus on the regulatory scene.
This is a crucial year for US-China biopharma and you won't want to miss this 2-day summit we're planning for you at the Shanghai Four Seasons, located in Pudong in the ultra-modern 21st Century Tower.